Crossmark

Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia

Crossref DOI link: https://doi.org/10.1186/s12878-019-0139-2

Published Online: 2019-05-02

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Greenfield, Graeme https://orcid.org/0000-0003-2333-1374
McMullan, Ross

Robson, Nuala

McGimpsey, Julie

Catherwood, Mark

McMullin, Mary Frances
License Information

Text and Data Mining valid from 2019-05-02
More Information

Article History

Received: 26 September 2018

Accepted: 8 April 2019

First Online: 2 May 2019

Ethics approval and consent to participate

: This study was a retrospective audit of care provided to each patient group in our region as a comparison to guidelines and published data. Implied consent for clinical audit purposes in line with standard practice. Data presented is not intended to be transferable and therefore as per Health Research Authority, UK guidelines does not require ethical approval.

: Not applicable.

: GG, RM, JM, NR, MC – no competing interests to declare.MFM – Novartis: Honorarium, speaker fee. Celgene: Speaker fee. Bristol Myer Squibb: Honorarium.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.